10 companies · 6 sourced backers · 73 milestones on record
Human gene editing aims to treat disease by changing DNA, from correcting individual letters to making larger rewrites. Companies are working to turn these methods into safe, effective medicines delivered directly inside the body, while others pursue ready-made cell therapies for cancer, autoimmune diseases and diabetes.
Where the 10 companies stand today, from their profiles and 10-year milestones. Tap a phase to see who is there.
- ▸Delivering editing tools safely inside the body
- ▸Proving precise DNA changes produce effective treatments in patients
- ▸Achieving durable benefits from a single treatment
- ▸Avoiding immune rejection without lifelong immune suppression
Publicly listed: 8 companies (owned by public shareholders).
- ›Every sourced story on all frontiers, filterable by company and news type
- ›10-year milestone records for each company: demo vs shipped
- ›Explained: plain-words readiness diagrams for real breakthroughs
- ›Signal Trends of 39 frontiers covering 378 companies over time.
- ›The events calendar: launches, approvals and deadlines ahead
- Arbor Biotechnologies
Full success would mean a portfolio of single-dose, in-vivo gene-editing cures for genetic diseases, powered by a continually expanding library of proprietar…
Lab · backed by ARCH Venture Partners
- Beam Therapeutics
To treat genetic disease by correcting individual DNA letters through base editing.
Lab · publicly listed
- Caribou Biosciences
Full success would mean delivering durable, off-the-shelf cell therapies that match or beat patient-specific (autologous) treatments for cancer and autoimmun…
Lab · publicly listed
- Editas Medicine
To treat genetic diseases with CRISPR-based gene editing.
Lab · publicly listed
- Intellia Therapeutics
To treat disease by editing DNA directly inside the body.
Trials · publicly listed
- Metagenomi
Full success would mean curative, single-administration in-vivo genetic medicines built from a proprietary library of novel editing systems — a goal Metageno…
Lab · publicly listed
- Prime Medicine
To treat genetic disease through precise search-and-replace changes to DNA.
Trials · publicly listed
- Sana Biotechnology
Full success would mean off-the-shelf, immune-evading cell therapies that cure or control diseases like type 1 diabetes and cancer without the need for lifel…
Lab · publicly listed
- Scribe Therapeutics
Full success would mean purpose-built, highly precise CRISPR tools that overcome the delivery and safety limits of first-generation editing — enabling a broa…
Lab · publicly listed · backed by Andreessen Horowitz, Casdin Capital
- Tessera Therapeutics
Full success would mean a versatile Gene Writing platform able to make nearly any genetic change needed to treat or cure disease — including large rewrites b…
Lab
Keep following breakthroughs like these. Every Monday, get up to 5 major breakthroughs and launches explained in plain English.
Free. No account needed. One email a week. Unsubscribe anytime.